BioSpace News Archive

What are your thoughts on companies mandating COVID-19 vaccines for employees? Are you open to getting vaccinated? Or are you still waiting for more research to be done on the different options?

The year 2020 and the COVID-19 pandemic created a number of challenges for individuals and companies. Despite these hurdles, Maryland-based Precigen still managed to achieve its clinical milestones in oncology.

Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced financial results and for the year ended December 31, 2020 and provided an update on recent corporate highlights.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that it will be participating in the Cell & Gene Meeting on the Mediterranean, which is being held virtually April 6 – 9, 2021,

The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy.

NanoVibronix, Inc. (the “Company”) (NASDAQ: NAOV) announced today that the Company’s Special Meeting of Stockholders, scheduled for 10:00 a.m. Eastern time today, March 31, 2021, has been adjourned to allow for more time for stockholders to vote.

Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone

Company is providing two million QuickVue® At-Home OTC COVID-19 Tests for “Say Yes! COVID Test” community health initiative in Pitt County, NC, and Chattanooga/Hamilton County, TN

CTI BioPharma Corp., a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, announced the pricing of its previously announced underwritten public offering of 14,260,800 shares of its common stock and 600 shares of its series X1 preferred stock.

FX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogel Proof-of-concept trial will evaluate safety and tolerability of FX301 administered as a peripheral analgesic nerve block in patients undergoing bunionectomy; initial data anticipated later this year